Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
6 pending office actions • 4 clients • 6 examiners • 5 art units • 0 of 6 (0%) have an AI response strategy ready
Maxwell L Minch Esq. PA has handled 201 career applications, primarily in the Biotechnology & Pharmaceuticals technology area. The firm maintains a resolved allowance rate pct of 69.44 for its resolved cases. Prosecution typically involves an avg office actions per allowance of 3.1.
There are currently 5 pending office actions under management. These active matters are situated within the Biotechnology & Pharmaceuticals sector, reflecting the firm's focus. The 201 career applications provide a foundation of experience for these ongoing cases.
The resolved allowance rate pct of 69.44 reflects the outcomes of Biotechnology & Pharmaceuticals prosecution. Achieving an allowance with an avg office actions per allowance of 3.1 indicates the firm's approach to overcoming examiner rejections. The firm's current 5 pending office actions follow these established prosecution patterns.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §112 only | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| MONTANARI, DAVID A | 1 | 64.7% | +49.0% |
| STOKLOSA, JOSEPH A | 1 | 63.8% | +19.7% |
| JOHNSON, KARA D | 1 | 69.5% | +24.6% |
| SU, SUSAN SHAN | 1 | 71.7% | +23.9% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17693457 | Methods And Compositions For Aesthetic And Cosmetic Treatment And Stimulating Hair Growth | JOHNSON, KARA D | 19d overdue |
| 17690814 | BANDAGE SYSTEM FOR WOUND VISUALIZATION, MICROCURRENT THERAPY AND TOPICAL AND TRANSDERMAL DRUG DELIVERY | SU, SUSAN SHAN | 9d |
| 17047411 | METHODS AND COMPOSITIONS FOR FORMULATING AND DISPENSING PHARMACEUTICAL FORMULATIONS | SCHUBERG, LAURA J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17693457 | Methods And Compositions For Aesthetic And Cosmetic Treatment And Stimulating Hair Growth | JOHNSON, KARA D | 19d overdue |
| 18233888 | Wearable lumbo-pelvic active balancing device and methods of use | STOKLOSA, JOSEPH A | 9d |
| 17690814 | BANDAGE SYSTEM FOR WOUND VISUALIZATION, MICROCURRENT THERAPY AND TOPICAL AND TRANSDERMAL DRUG DELIVERY | SU, SUSAN SHAN | 9d |
| 19333338 | GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | CANELLA, KAREN A | — |
| 18866750 | GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY | MONTANARI, DAVID A | — |
| 17047411 | METHODS AND COMPOSITIONS FOR FORMULATING AND DISPENSING PHARMACEUTICAL FORMULATIONS | SCHUBERG, LAURA J | — |
| Client (Assignee) | Pending OAs |
|---|---|
| PLURI BIOTECH LTD. | 3 |
| Hadasit Medical Research Services and Development | 1 |
| SYMETRIFY LTD. | 1 |
| CLEAR CARE PRODUCTS, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1643 | 1 |
| 3794 | 1 |
| 3781 | 1 |
| 1631 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19333338 | GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | Pluri Biotech Ltd. | CANELLA, KAREN A | 1643 | §112 | Final Rejection | — | Pending | Sep 18, 2025 |
| 18866750 | GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY | Hadasit Medical Research Services And Development Ltd. | MONTANARI, DAVID A | 1632 | §103 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18233888 | Wearable lumbo-pelvic active balancing device and methods of use | Symetrify Ltd. | STOKLOSA, JOSEPH A | 3794 | §112 | Non-Final OA | 9d | Pending | Aug 15, 2023 |
| 17693457 | Methods And Compositions For Aesthetic And Cosmetic Treatment And Stimulating Hair Growth | Pluri Biotech Ltd. | JOHNSON, KARA D | 1632 | §103§112 | Non-Final OA | 19d overdue | Pending | Mar 14, 2022 |
| 17690814 | BANDAGE SYSTEM FOR WOUND VISUALIZATION, MICROCURRENT THERAPY AND TOPICAL AND TRANSDERMAL DRUG DELIVERY | Clear Care Products, Inc. | SU, SUSAN SHAN | 3781 | §103§112Other | Non-Final OA | 9d | Pending | Mar 09, 2022 |
| 17047411 | METHODS AND COMPOSITIONS FOR FORMULATING AND DISPENSING PHARMACEUTICAL FORMULATIONS | Pluri Biotech Ltd. | SCHUBERG, LAURA J | 1631 | §103 | Final Rejection | — | Pending | Oct 14, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial